Two phase III trials evaluating once-daily Simeprevir and

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 2, 2014 at 7:15 AM

Two phase III trials evaluating once-daily Simeprevir and Sofosbuvir in hepatitis C infected patients have been initiated

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that two phase III trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naïve and treatment-experienced patients with and without cirrhosis. “Positive safety and efficacy results have previously been demonstrated in genotype 1 HCV infected patients with the interferon- and ribavirin free combination of simeprevir and sofosbuvir in the phase II COSMOS study. The OPTIMIST trials aim to further consolidate these data and to explore a shorter treatment duration of eight weeks to potentially further simplify this promising treatment option,” says Charlotte Edenius, EVP Development, Medivir AB Study design OPTIMIST-1 The first trial, called OPTIMIST-1 or TMC435HPC3017, is a phase III, open-label, randomized study investigating the efficacy and safety of simeprevir 150 mg in combination with sofosbuvir 400 mg. The combination will be administered once daily for 8 or 12 weeks in chronic HCV genotype 1 infected patients without cirrhosis who are HCV treatment naïve or treatment experienced. This study will enroll approximately 300 patients in the U.S. and Canada. OPTIMIST-2 The second trial, called OPTIMIST-2 or TMC435HPC3018, is a phase III, open -label, single-arm study investigating the efficacy and safety of simeprevir 150 mg in combination with sofosbuvir 400 mg. The combination will be administered once daily for 12 weeks in HCV genotype 1 infected patients with cirrhosis who are HCV treatment naïve or treatment experienced. This study will enroll approximately 100 patients in the U.S. and Canada. Ribavirin will not be administered in the OPTIMIST trials. The primary efficacy endpoint in each study is the proportion of patients achieving sustained virologic response 12 weeks after the end of treatment (SVR12). For additional information, including inclusion and exclusion criteria for these trials, please visit www.clinicaltrials.gov COSMOS study The combination of simeprevir and sofosbuvir was previously evaluated in the phase II COSMOS trial. The final cohort 1 study results (SVR12) in patients without fibrosis or cirrhosis (METAVIR score of F0-2) and the interim cohort 2 study results (SVR4) in patients with fibrosis or cirrhosis (METAVIR score of F3-4) from the COSMOS study were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2013 in Washington, D.C. Final cohort 2 results (SVR12) have been accepted for presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2014 on April 12. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.00 CET on 2 April 2014. About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB will retain marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. The treatment was approved for the treatment of genotype 1 hepatitis C in September 2013 in Japan and in November 2013 in Canada and the U.S. and in March 2014 in Russia. The Committee for Medicinal Products for Human Use (CHMP) recently recommended Marketing Authorisation in the European Union for the use of Simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. An approval is expected during Q2-2014. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pre-Owned Jet Inventory Rises; Price Trends Unclear

October's Pre-Owned Aircraft Inventory: A Mixed Bag Nothing like leafing through October's data on pre-owned jets and feeling your stomach do that weird flip-flop. Inventory's nudging up, but it's still on its knees compared to last year's numbers. According to Sandhills Global's fresh aviation market reports, we got an increase in what's available on platforms like...

Maritime Injury Law: Neidzwski Talks Sea Changes

Legal waters are as choppy as the seas themselves, especially in the maritime injury law arena. Nicholas J. Neidzwski, a maritime injury attorney and partner at BoatLaw, LLP, recently waded into these turbulent waters at the 2026 Pacific Admiralty Seminar. This isn’t just any gathering; it’s the West Coast’s legal beacon on all things maritime, drawing in industry...

Andersen's Window Revamp: Addressing Demand Surge

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

Milton Hershey School's New Project: Founders Grove Launches

Breaking New Ground with Founders Grove It’s not every day a community gets a new lease on life through bricks and mortar, but Milton Hershey School (MHS) just did exactly that. They've broken ground on Founders Grove, a piece of the Hershey West End development puzzle that reflects both history and future potential. This isn’t just another housing project—this...

LINC Faces Class Action, Investors Eye November Deadline

Lincoln's Class Action Battle: What's at Stake It's no picnic in the stock-trading trenches, especially with the heat Lincoln Education Services Corporation is catching. The class action suit flashing headlines is a big deal, folks, and it hinges on Lincoln's alleged fibs about student enrollments. With a lead plaintiff deadline looming on November 10, 2026, investors...

VS Pharmtech Enhances Cancer Drug Efficiency, Eyes IPO

Revolutionizing Cancer Care, One Dose at a Time Now, here's a twist worth chewing over your morning coffee: VS Pharmtech isn't concocting some newfangled miracle drug but is instead jazzing up the old ones. Their creation, VS-101, isn't just another treatment—it's a radiosensitizer designed to make existing therapies more potent without the toxic baggage. The Science...

Mount St. Mary's Expands Pathways with SJR MOU

Catholic Education Steps Up the Game You know, it’s not every day you bump into a move that feels like a real win-win in the education sector. But here we are, watching this shiny new partnership between Mount St. Mary's University and Saint Joseph Regional High School unfold. The pair signed a fresh memorandum of understanding (MOU) that’s got everyone...

AZZ Inc.'s 2026 Sustainability Report: A Closer Look

Diving into AZZ's Sustainability Commitment AZZ Inc., known in the trading circles as NYSE:AZZ, has just dropped its 2026 Sustainability Report and it’s quite the document to chew on. This ain't your typical corporate fluff. Tom Ferguson, the man steering the AZZ ship, laid it down plain and simple. This report isn’t just about ticking boxes for ESG; it’s reflecting...

APP Group's New Conservation Efforts in Sumatra

Taking a Bold Step Towards Conservation APP Group, in collaboration with Proforest, WWF-Indonesia, and KKI WARSI, is setting its sights on a more sustainable future with the PROTECT30 initiative. This isn't just another dime-a-dozen CSR project—it’s a concerted effort aimed at conserving Sumatra's precious Bukit Tigapuluh landscape. These folks are playing the long...

Buying a Home in East Grand Rapids: Key Tips Revealed

Navigating East Grand Rapids Housing Market Jumping into the housing market in East Grand Rapids, Michigan, is like diving headfirst into a spirited game of musical chairs. Blink, and that dream property might have slipped through your fingers. The competition here is fierce, and if you're not coming prepared, you're setting yourself up for a world of disappointment....